Similar articles

• [Immunotherapy with monoclonal antibody of malignant lymphoma].

  Ogura M. Ogura M. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:545-60. Nihon Rinsho. 2007. PMID: 17474462 Review. Japanese. No abstract available.
• Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

  Sikder MA, Friedberg JW. Sikder MA, et al. Curr Oncol Rep. 2008 Sep;10(5):420-6. doi: 10.1007/s11912-008-0064-1. Curr Oncol Rep. 2008. PMID: 18706270 Review.
• Novel antibodies against follicular non-Hodgkin's lymphoma.

  van Meerten T, Hagenbeek A. van Meerten T, et al. Best Pract Res Clin Haematol. 2011 Jun;24(2):231-56. doi: 10.1016/j.beha.2011.03.002. Epub 2011 May 5. Best Pract Res Clin Haematol. 2011. PMID: 21658621 Review.
• Anti-CD20 antibody therapy is highly effective in the treatment of follicular lymphoma.

  Marshall H. Marshall H. Trends Immunol. 2001 Apr;22(4):183-4. doi: 10.1016/s1471-4906(01)01909-3. Trends Immunol. 2001. PMID: 11274916 No abstract available.
• Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?

  Kahl B. Kahl B. Hematology Am Soc Hematol Educ Program. 2012;2012:433-8. doi: 10.1182/asheducation-2012.1.433. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233615 Review.